Poor self-reported sleep quality and health-related quality of life in patients with chronic fatigue syndrome/myalgic encephalomyelitis.
Castro-Marrero, Jesús, Zaragozá, Maria C, González-Garcia, Sergio et al. · Journal of sleep research · 2018 · DOI
Quick Summary
This study looked at sleep problems in 1,455 Spanish ME/CFS patients and found that nearly all of them reported poor sleep quality that wasn't refreshing, even when they slept. The researchers discovered that poor sleep was strongly linked to worse pain, fatigue, anxiety, depression, and lower quality of life overall. Several factors—including pain intensity, mood problems, fibromyalgia, and autonomic nervous system dysfunction—were particularly associated with sleep difficulties.
Why It Matters
Sleep disturbance is a core diagnostic feature of ME/CFS, yet this study provides rare large-scale data on how pervasive and severe self-reported sleep problems are in this population. Understanding the associations between sleep quality and other symptoms helps clinicians recognize interconnected symptom clusters and may inform targeted interventions to improve quality of life.
Observed Findings
Over 80% of the cohort reported symptom clusters across muscular, cognitive, neurological, autonomic, and immunological domains.
Sleep quality correlated significantly (p < 0.01) with pain, fatigue, psychopathological status, anxiety/depression, functional capacity, and overall health-related quality of life.
Pain intensity (OR 1.11), psychopathological status (OR 1.85), fibromyalgia (OR 1.39), and severe autonomic dysfunction (OR 1.72) were independently associated with poor sleep quality after adjusting for age and gender.
Poor functional capacity and reduced quality of life were significantly associated with poor sleep quality (OR 0.96-0.98, p < 0.001).
Inferred Conclusions
Poor sleep quality is a prevalent and significant problem in ME/CFS patients and is associated with multiple dimensions of impaired health-related quality of life.
Psychopathological status and autonomic dysfunction are particularly strong correlates of sleep disturbance in this population.
Sleep quality may serve as an important therapeutic target for improving overall symptom burden and quality of life in ME/CFS.
Remaining Questions
Does improving sleep quality lead to improvements in pain, fatigue, and functional capacity, or do these improvements require independent intervention?
What are the objective sleep architecture abnormalities (via polysomnography) underlying the self-reported poor sleep quality in ME/CFS?
What This Study Does Not Prove
This study cannot establish causation—it does not prove that poor sleep causes other symptoms or vice versa, only that they co-occur. It relies entirely on patient self-report without objective sleep measurements such as polysomnography, which may not capture actual sleep architecture or objective sleep duration. The cross-sectional design prevents determining whether addressing sleep quality would improve other symptoms.
Are specific sleep interventions (behavioral, pharmacological, or other) effective and safe in ME/CFS patients, and do they improve downstream outcomes?
How do sleep disturbances in ME/CFS differ mechanistically from primary sleep disorders or other chronic conditions?